GU Cancers 2021 | CTC enumeration as a prognostic biomarker in prostate cancer

Howard Scher, MD, FASCO, Memorial Sloan-Kettering Cancer Center, New York, NY, discusses the development and validation of circulating tumor cell (CTC) enumeration, determined on the Epic Sciences platform, as a prognostic biomarker in men with metastatic castration-resistant prostate cancer (mCRPC). In the discovery cohort, CTC count was found to be a statistically significant prognostic factor of overall survival. These findings were then validated using data from the PROPHECY trial (NCT02269982). This interview took place during the 2021 Genitourinary Cancers Symposium.